Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Open Philanthropy Project

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 17
Average round size
info
The average size of a deal this fund participated in
$47M
Portfolio companies 12
Rounds per year 1.89
Lead investments 5
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.29
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Non Profit
  • Health Care
  • Communities
  • Education
Summary

In 2014 was created Open Philanthropy Project, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the San Francisco. The company was established in North America in United States.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Open Philanthropy Project, startups are often financed by Temasek Holdings, Sailing Capital, Raj Luhar. The meaningful sponsors for the fund in investment in the same round are William Adams, Viking Global Investors, UBS. In the next rounds fund is usually obtained by Vikrant Bhargava, Shakil Khan, Sebastian Pollok.

Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Social Entrepreneurship, Nutrition. Among the most popular portfolio startups of the fund, we may highlight Impossible Foods.

The fund is constantly included in less than 2 investment rounds annually. When the investment is from Open Philanthropy Project the average startup value is more than 1 billion dollars. Speaking about the real fund results, this Corporate Investor is 40 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2019. Deals in the range of 50 - 100 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Open Philanthropy Project:
Typical Co-investors
Open Philanthropy Project is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Open Philanthropy Project:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AFSquare California, Culver City, United States
Berninger Verwaltungs GmbH Bayern, Germany, Gräfelfing
Broken Arrow Venture Capital California, Los Altos, United States
Falls Angel Fund -
Gerako Espoo, Finland, Uusimaa
Global Financial Services Opportunity Fund -
Kenda Capital Rijswijk, The Netherlands, Zuid-Holland
Matmut France, Haute-Normandie, Rouen
Ningbo Guangmu Touzi China, Ningbo, Zhejiang
Nippon Kouatsu Electric Co Aichi Prefecture, Japan, Obu
Pi Capital England, London, United Kingdom
Shenzhen Aoto Electronics China, Guangdong, Tianjin
Startup Education -
Topspin Fund -
VARECO HOLDINGS -
Weien Touzi China, Japan, Kagoshima Prefecture

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Alvea

Biotechnology
Pharmaceutical
$19M01 Jan 2022 Cambridge, Massachusetts, United States

Icosavax

Biotechnology
Health Care
Pharmaceutical
$100M07 Apr 2021 Seattle, Washington, United States

Sherlock Biosciences

Biotechnology
Health Care
Health Diagnostics
Life Science
$7M21 May 2020 Cambridge, Massachusetts, United States

Impossible Foods

Cooking
Food and Beverage
Food Processing
Nutrition
Organic Food
$300M01 May 2019 Redwood City, California, United States

Sherlock Biosciences

Biotechnology
Health Care
Health Diagnostics
Life Science
$31M23 Apr 2019 Cambridge, Massachusetts, United States

Founders Pledge

Charity
Communities
Financial Services
Non Profit
Social Entrepreneurship
$2M08 Apr 2019 London, England, United Kingdom

Sherlock Biosciences

Biotechnology
Health Care
Health Diagnostics
Life Science
$17M22 Mar 2019 Cambridge, Massachusetts, United States

Institute for Protein Design - Crunchbase School Profile & Alumni

Biotechnology
Education
$11M05 Apr 2018 Seattle, Washington, United States

Founders Pledge

Charity
Communities
Financial Services
Non Profit
Social Entrepreneurship
$3M20 Mar 2018 London, England, United Kingdom
News
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials

– Icosavax closed a $100m Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, and Surveyor Capital (a Citadel company).
– A previously announced funding from Open Philanthropy was included in this round.
– The proceeds of the financing will support the development of Icosavax’s bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine program through initial clinical studies, continued evaluation of its SARS-CoV-2 vaccine candidate, and further expansion of the company’s pipeline of VLP vaccine candidates focused on protecting older adults from life-threatening respiratory diseases.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Open Philanthropy Project?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: